戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of the order Mucorales (the fungi that cause mucormycosis).
2 ic ulcer biopsy revealed invasive intestinal mucormycosis.
3 mprehensive imaging studies in patients with mucormycosis.
4  as a strategy to improve outcomes of deadly mucormycosis.
5 ic immune serum protected mice with DKA from mucormycosis.
6 available serum iron predisposes the host to mucormycosis.
7 tion by endosymbionts in the pathogenesis of mucormycosis.
8 available serum iron predisposes the host to mucormycosis.
9 o enhanced the host inflammatory response to mucormycosis.
10  US FDA, is a highly effective treatment for mucormycosis.
11 es predispose to certain infections, such as mucormycosis.
12 ressors can be a vehicle for transmission of mucormycosis.
13 A, two unspecified IMD, and one disseminated mucormycosis.
14 are essential for improving the prognosis of mucormycosis.
15 D-19-associated rhino-orbital-cerebral (ROC) mucormycosis.
16 and unpublished cases of COVID-19-associated mucormycosis.
17 bronchoalveolar lavage fluids for diagnosing mucormycosis.
18 tential for enhancing the rapid detection of mucormycosis.
19 dality that allows non-invasive diagnosis of mucormycosis.
20 shock, organ necrosis and death in mice with mucormycosis.
21 ketoacidosis (DKA) and neutropenic mice from mucormycosis.
22 ation are at high risk of invasive pulmonary mucormycosis.
23  with pulmonary, disseminated, and localized mucormycosis.
24 lar lavage (BAL) fluids for the diagnosis of mucormycosis.
25 ologists interpreting imaging studies of ROC mucormycosis.
26 d outcomes in immunosuppressed patients with mucormycosis.
27 CR) for the early diagnosis and follow-up of mucormycosis.
28 ed virulence in both fly and mouse models of mucormycosis.
29 tential for improving the rapid diagnosis of mucormycosis.
30  the use of statins as adjunctive therapy in mucormycosis.
31 tatins on Rhizopus oryzae, a common cause of mucormycosis.
32  the treatment of invasive aspergillosis and mucormycosis.
33 atients, who have increased GRP78 levels, to mucormycosis.
34 nvade host cells and protected DKA mice from mucormycosis.
35               Angioinvasion is a hallmark of mucormycosis.
36 eutic target for prevention and treatment of mucormycosis.
37 a diabetic ketoacidotic (DKA) mouse model of mucormycosis.
38 puted tomographic (CT) scan of patients with mucormycosis.
39 y CotH as a promising therapeutic target for mucormycosis.
40 azole monotherapy, in the cutaneous model of mucormycosis.
41 a) and a nonlethal murine model of cutaneous mucormycosis.
42 ivo in 2 phylogenetically distinct models of mucormycosis.
43 orales species most commonly associated with mucormycosis.
44 s more often been used as a synonym only for mucormycosis.
45 so reviews the key advances against invasive mucormycosis.
46 rove the rate of early diagnosis of invasive mucormycosis.
47 or allogeneic HSCT recipients suffering from mucormycosis.
48 demiology and the clinical manifestations of mucormycosis.
49 t highly aggressive, mold infections such as mucormycosis.
50  and its subsequent impact on the outcome of mucormycosis.
51 occurred in 14.8% (4 of 27; aspergillosis 3, mucormycosis 1).
52 ively) and higher for subjects with invasive mucormycosis (100%) compared with aspergillosis (45.7%).
53 mples from 10 patients diagnosed with proven mucormycosis (2-9 samples per patient) were analyzed.
54                               Of 29 cases of mucormycosis, 27 had tissue samples available for PCR an
55 d with improved survival in the fly model of mucormycosis (65% vs 57% posaconazole alone) and with si
56 een in the midst of a notifiable epidemic of mucormycosis (a rare angio-invasive fungal infection), w
57           Fungi of the order Mucorales cause mucormycosis, a lethal infection with an incompletely un
58 nical syndromes, for example, "rhinocerebral mucormycosis." A list of major recommended human and ani
59  the treatment of invasive aspergillosis and mucormycosis after solid organ transplantation (SOT).
60   Thirteen BAL samples from 13 patients with mucormycosis, all of which tested positive for Mucorales
61                                              Mucormycosis also remains a threat in patients with diab
62    We report a cluster of cases of cutaneous mucormycosis among Joplin tornado survivors that were as
63 investigated a cluster of cases of cutaneous mucormycosis among persons injured during the May 22, 20
64  Rhizopus oryzae is the most common cause of mucormycosis, an angioinvasive fungal infection that cau
65 toacidosis (DKA) are uniquely predisposed to mucormycosis, an angioinvasive fungal infection with hig
66          One such example is the increase of mucormycosis, an invasive infection caused by filamentou
67 ed after mobilization, one from disseminated mucormycosis and another from active lupus after postpon
68 and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin
69  useful for confirmation of the diagnosis of mucormycosis and for further characterization of the inf
70   Isavuconazole can be used for treatment of mucormycosis and is well tolerated.
71 nique susceptibility of patients with DKA to mucormycosis and provide a foundation for the developmen
72 e were presumptively identified as agents of mucormycosis and referred to the Mycology Reference Labo
73            Understanding the pathogenesis of mucormycosis and the host response to invading hyphae ul
74 owever, given the human and economic cost of mucormycosis and the need for rapid diagnosis to initiat
75    Histopathology confirmed the diagnosis of mucormycosis and the patient improved post-operatively o
76 f available iron are uniquely susceptible to mucormycosis and these infections are highly angioinvasi
77 eiterates the reasons why the classic names "mucormycosis" and "entomophthoramycosis" are more approp
78 initions, 47 patients had proven or probable mucormycosis, and 171 did not have invasive Mucorales in
79 alert the hematologist to the possibility of mucormycosis, and aggressive and timely treatment approa
80 nocandins, their synergy in murine models of mucormycosis, and observational clinical data that are c
81  prophylaxis and treatment of aspergillosis, mucormycosis, and other invasive fungal infections.
82 for the diagnosis of invasive aspergillosis, mucormycosis, and Pneumocystis pneumonia.
83 nt in most patients with COVID-19-associated mucormycosis, and rhino-orbital cerebral mucormycosis wa
84 ve pulmonary aspergillosis (IPA), seven with mucormycosis, and three with nocardiosis.
85                            Upon suspicion of mucormycosis appropriate imaging is strongly recommended
86 s, both invasive pulmonary aspergillosis and mucormycosis are associated with "atypical" nonnodular p
87 nd pitfalls in designing clinical studies of mucormycosis are discussed in this article.
88          New strategies to prevent and treat mucormycosis are urgently needed.
89 minimize breakthrough infection or relapsing mucormycosis associated with inadequate blood concentrat
90 ll transplant patients diagnosed with proven mucormycosis between 2001 and 2009 at Brigham and Women'
91  the hypodense sign are typical of pulmonary mucormycosis but occur less frequently.
92 s mucoricin important in the pathogenesis of mucormycosis but our data suggest that a ricin-like toxi
93                                              Mucormycosis, but not aspergillosis patients, with repea
94 acidosis and became extremely susceptible to mucormycosis, but not aspergillosis, while sodium bicarb
95 s positive in three of seven cases of proven mucormycosis, but the cultures were negative in all.
96 th and has valuable potential for diagnosing mucormycosis by enhancing discriminatory detection of Mu
97 unusually high number of COVID-19-associated mucormycosis (CAM) cases reported during this same perio
98  of COVID-19-associated rhino-orbitocerebral mucormycosis (CAM) has occurred in many parts of the wor
99              Based on anatomic localization, mucormycosis can be classified as one of 6 forms: (1) rh
100 w, the most common bIFIs were aspergillosis, mucormycosis, candidiasis, and fusariosis.
101     In an investigation of hospital-acquired mucormycosis cases among transplant recipients, healthca
102                                              Mucormycosis cases treated with isavuconazole as primary
103 lls in five Mucorales species, including key mucormycosis causative agents like Rhizopus and Mucor sp
104                        We report an invasive mucormycosis caused by Actinomucor elegans in a patient
105 e in only 1 patient with proven disseminated mucormycosis caused by Lichtheimia species.
106  2 clinicopathologically different diseases, mucormycosis caused by members of Mucorales and entomoph
107                                              Mucormycosis causes mortality in at least 50% of cases d
108 pp are the most common etiological agents of mucormycosis, causing over 90% mortality in disseminated
109                                     Invasive mucormycosis comprises a group of uncommon but emerging
110 anges of the causative species, for example, mucormycosis covers numerous mucormycetous molds.
111 abetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved surviva
112 ions and right-angle branching suggestive of mucormycosis demonstrated by Periodic acid-Schiff stain.
113                                Management of mucormycosis depends on recognising disease patterns and
114 e detection of circulating Mucorales DNA for mucormycosis diagnosis and follow-up after treatment ini
115  of 10 patients between 68 and 3 days before mucormycosis diagnosis was confirmed by histopathologica
116 first published report of a clinical case of mucormycosis due to M. velutinosus, as well as a rare ca
117 l transplantation who developed disseminated mucormycosis due to Rhizomucor pusillus/R. miehei involv
118  vivo in a mouse model of invasive pulmonary mucormycosis due to Rhyzopus delemar infection.
119      Our results dissect the pathogenesis of mucormycosis during ketoacidosis and reinforce the impor
120    We exhaustively reviewed all the cases of mucormycosis (European Organisation for Research and Tre
121 ition, it's important to consider intestinal mucormycosis even in patients who are immunocompetent wi
122 h DKA, which have enhanced susceptibility to mucormycosis, exhibited increased expression of GRP78 in
123     We hereby report a case of rhino-orbital mucormycosis following P.vivax malaria in a 20-year-old
124                                              Mucormycosis has emerged as an important opportunistic i
125                                              Mucormycosis has emerged as the third most common invasi
126                      The global incidence of mucormycosis has increased in recent years owing to high
127 he first-line therapy for invasive pulmonary mucormycosis, has been shown to promote or inhibit repli
128               Reports of COVID-19-associated mucormycosis have been increasing in frequency since ear
129 gic malignancy patients who develop invasive mucormycosis have not significantly improved over the pa
130 se encephalitis), endemic fungal infections (mucormycosis, histoplasmosis, talaromycosis, sporotricho
131 is is the first report of transdiaphragmatic mucormycosis in a series of 3 patients.
132                            The occurrence of mucormycosis in an immunocompetent patient is rare.
133  species of Mucorales for early diagnosis of mucormycosis in at-risk patients.
134  fungal pathogen capable of causing invasive mucormycosis in humans.
135 vasive testing modality for the diagnosis of mucormycosis in immunosuppressed patients and those with
136       There is high background prevalence of mucormycosis in India likely from a high prevalence of r
137 ropriate first-line therapeutic strategy for mucormycosis in organ and stem cell transplant recipient
138 to illustrate the entire imaging spectrum of mucormycosis in the head-neck-face region.
139 d rhizoxin contribute to the pathogenesis of mucormycosis in the models studied.
140                    Laboratory assessment for mucormycosis includes the conventional methods of direct
141 nosis and treatment of gastrointestinal (GI) mucormycosis infection is critical but can be challengin
142       Because angioinvasion is a hallmark of mucormycosis infections, we sought to define the endothe
143                             During pulmonary mucormycosis, inhaled sporangiospores adhere to, germina
144                                              Mucormycosis is a deadly invasive fungal infection whose
145                                              Mucormycosis is a destructive invasive mold infection af
146                                              Mucormycosis is a devastating disease and can occur in p
147                                              Mucormycosis is a devastating invasive fungal disease wh
148                                              Mucormycosis is a difficult to diagnose rare disease wit
149                                              Mucormycosis is a fungal infection caused by environment
150                                              Mucormycosis is a fungal infection caused by Mucorales f
151                                              Mucormycosis is a fungal infection of the sinuses, brain
152                                              Mucormycosis is a life-threatening infection caused by M
153                                              Mucormycosis is a life-threatening infection that occurs
154                                              Mucormycosis is a life-threatening infection.
155                                              Mucormycosis is a life-threatening mold infection affect
156                                              Mucormycosis is a potentially lethal, angioinvasive fung
157                                              Mucormycosis is a severe emerging invasive fungal infect
158                                              Mucormycosis is an aggressive invasive fungal infection
159                                              Mucormycosis is an emerging angioinvasive infection caus
160                                              Mucormycosis is an uncommon invasive fungal disease with
161 ur Review indicates that COVID-19-associated mucormycosis is associated with high morbidity and morta
162                                              Mucormycosis is difficult to diagnose.
163                                              Mucormycosis is estimated at around 60 cases annually.
164 he mortality rate after rhino-orbitocerebral mucormycosis is high and that a subgroup of patients wit
165                  Early diagnosis of invasive mucormycosis is important for timely therapeutic interve
166                        However, diagnosis of mucormycosis is often delayed due to the lack of a non-i
167                       Diagnosis of pulmonary mucormycosis is particularly challenging, and might be f
168                                              Mucormycosis is rare, life-threatening fungal infection.
169                               Invasive wound mucormycosis (IWM) is associated with an extremely poor
170 iseases, among which includes invasive wound mucormycosis (IWM), are associated with poor outcomes in
171 gnostic gaps: lack of molecular detection of mucormycosis; lack of an optimal diagnostic algorithm in
172 ve aspergillosis (Aspergillus fumigatus) and mucormycosis (Lichtheimia corymbifera) murine models tha
173                                              Mucormycosis localization remained the only independent
174 s regions analysed the published evidence on mucormycosis management and provided consensus recommend
175 losis and other mycoses, including agents of mucormycosis may also be transmitted from infected donor
176 mine how pharmacological aspects of treating mucormycosis may differ from those of the more commonly
177 chitin concentrations), and in vivo, using 2 mucormycosis models: an invertebrate model (Drosophila)
178                                              Mucormycosis most often occurs late, >3 months after tra
179 ecause of invasive aspergillosis (n = 71) or mucormycosis (n = 10).
180  mandatory to identify healthcare-associated mucormycosis, notably in neonatology, hematological, and
181                                              Mucormycosis now represents a major threat in transplant
182                                      Data on mucormycosis obtained in France between 2005 and 2007 fr
183                 However, invasive intestinal mucormycosis occurring in immunocompetent individuals wi
184 at HIF1alpha plays two opposing roles during mucormycosis: one that facilitates the ability of Mucora
185 e to patients with pulmonary or disseminated mucormycosis or cerebral involvement.
186                                              Mucormycosis outbreaks have been linked to contaminated
187 with an important role for these proteins in mucormycosis pathogenesis.
188                            Aspergillosis and mucormycosis patients with higher baseline CT (CT >40 an
189                                              Mucormycosis patients with higher baseline CT had a sign
190                                    Pulmonary mucormycosis (PM) is a life-threatening fungal infection
191 ngal infections are caused by aspergillosis, mucormycosis, pneumocystis, cryptococcus, and candida.
192                                 Diagnosis of mucormycosis poses a substantial challenge due to the la
193 22, 2008, to June 21, 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 d
194  with disseminated, pulmonary, and localized mucormycosis, respectively.
195 s used by the most common etiologic agent of mucormycosis, Rhizopus oryzae.
196 leled by an outbreak of rhino-oculo-cerebral mucormycosis (ROCM) a fungal infection affecting the nos
197                         Rhino-orbitocerebral mucormycosis (ROCM) caused by more common zygomycetes (e
198         We report the first case of invasive mucormycosis secondary to Actinomucor elegans infection.
199 imary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was
200 s of malaria, cysticercosis, histoplasmosis, mucormycosis, subacute sclerosing panencephalitis, and A
201 es the probability of the patient developing mucormycosis, suggesting that bacteria have the potentia
202 igh sensitivity and specificity for invasive mucormycosis suggests it could be useful for early treat
203  early recognition and treatment of invasive mucormycosis syndromes, as well as individualized approa
204 es have reported the estimated prevalence of mucormycosis to be around 70 times higher in India as co
205  an accurate and rapid diagnosis of invasive mucormycosis to guide the timely initiation of amphoteri
206 ts diagnosed with invasive aspergillosis and mucormycosis using plasma cell-free DNA (cfDNA) PCR were
207 g COVID-19 patients, with invasive pulmonary mucormycosis, using AmB.IMPORTANCEAmB and nystatin are c
208 ted mucormycosis, and rhino-orbital cerebral mucormycosis was the most frequent disease.
209 ed for treatment of invasive Aspergillus and mucormycosis, we observed an increased rate of bIFI, not
210 oacidosis (DKA), are uniquely susceptible to mucormycosis, we sought to define the role of iron and g
211  additional patients with proven or probable mucormycosis were included to analyze DNA load kinetics.
212 ngal disease caused by rare fungi, including mucormycosis, were recruited from 34 centres worldwide.
213 iagnostic tool for non-invasive diagnosis of mucormycosis, which may enable early treatment and impro
214 y shows the diverse clinical presentation of mucormycosis with a high prevalence of primary skin infe
215 e to treat patients with invasive intestinal mucormycosis with aggressive antifungal and supportive c
216 have been published where patients developed mucormycosis with associated malarial infection.
217 irox therapy to improve the poor outcomes of mucormycosis with current therapy.
218                   The high mortality rate of mucormycosis with currently available monotherapy, parti
219        Isavuconazole showed activity against mucormycosis with efficacy similar to amphotericin B.
220                       Such an association of mucormycosis with malaria infection is rarely reported i
221 of Rhizopus oryzae, the most common cause of mucormycosis, with reduced CotH expression was impaired
222 eased survival in a mouse model of pulmonary mucormycosis without reducing fungal burden.

 
Page Top